When control over prescription drug access rests with only a few players, the result is not just market imbalance — it is higher plan costs, increased financial pressures, and ultimately reduced affordability for patients.Across industries, competition between a few dominant players is not unusual, but in healthcare, its effects extend well beyond standard business rivalry. […]
